Search Clinical Trials

Clinical Trials Category

All of Us Research Program

Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.

25 results for "Cancer" and "Eye/Orbital Cancers"

A Phase 2, Randomized, Open-label, 3-arm Study of Relacorilant in Combination with Nab-Paclitaxel for Patients with Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or continuous regimens of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel alone.
Protocol No
CORCEPT-CORT125134-552
Sub Category
Gynecologic Cancers

An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Protocol No
GENENTECH-MYPATHWAY
Sub Category
Breast Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Sarcoma
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers
Gynecologic Cancers
Gastrointestinal Cancers
Endocrine Cancers

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Protocol No
TORAY-950P1V02
Sub Category
Breast Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Sarcoma
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers
Gynecologic Cancers
Gastrointestinal Cancers

Molecular Analysis for Therapy Choice (MATCH)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Protocol No
ECOG-EAY131-MATCH
Sub Category
Hematologic/Blood Related Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Sarcoma
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers
Gynecologic Cancers
Gastrointestinal Cancers
Eye/Orbital Cancers
Endocrine Cancers
Breast Cancers
Brain and Spine Cancers

The OVAL Study: A Randomized, Controlled, Double-Arm,Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for theTreatment of Recurrent Platinum-Resistant Ovarian Cancer

To assess how well the combination of intravenous administration of VB-111 and paclitaxel compared to placebo and paclitaxel in patients with platinum resistant ovarian cancer as measured by Overall Survival.
Protocol No
GOG-3018-VBL-VB-111-701
Sub Category
Gynecologic Cancers

A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

The purpose of the study is to compare any good and bad effects of using a combination of the investigational agents cediranib and olaparib, to using the standard chemotherapy, or cediranib alone, or olaparib alone.
Protocol No
NRG-GY005
Sub Category
Gynecologic Cancers

Phase I-II Study Evaluating the Dosing, Safety, Efficacy and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

The objective is to evaluate safety and compare progression free survival between subjects receiving neoadjuvant chemotherapy (NACT) plus GEN-1 versus NACT alone
Protocol No
CELSION-201-17-201
Sub Category
Gynecologic Cancers

Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer

The purpose of this study is to compare any good and bad effects of avoiding the hippocampus during whole-brain radiation to the usual whole-brain radiation. The hippocampus is part of the brain that is important for memory. Avoiding the hippocampus during whole-brain radiation could decrease the chance of side effects on memory and thinking. It also is possible that avoiding the hippocampus could have no benefit or could cause other side effects. Hippocampal avoidance also could lessen the effectiveness of whole-brain radiation. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. To be better, the addition of the hippocampal avoidance technique to whole-brain radiation therapy should decrease the chance of side effects on memory or thinking by at least 14.5%.
Protocol No
NRG-CC003
Sub Category
Brain and Spine Cancers
Thoracic Cancers
Share This: